Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines
Julie A. Vendrell(Inserm), Pascale A. Cohen(Lyon 1 Université), Éric Badia(Inserm), Catherine Desmetz(Centre des Sciences du Goût et de l'Alimentation), Catherine Nguyen(Cooper Medical School of Rowan University), Rosette Lidereau(Inserm), Sengül Tozlu(Inserm), Jean‐Claude Nicolas(Hôpital Lapeyronie), Ivan Bièche(Centre National de la Recherche Scientifique)
Cited by 45
Related Papers
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach
|Endocrine Related Cancer|2006|239
Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function
|Drug Metabolism and Disposition|2009|180